Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma

Thomas Jandl, Ekaterina Revskaya, Zewei Jiang, Ruth A. Bryan, Arturo Casadevall, Ekaterina Dadachova

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: Novel treatments for metastatic melanoma are urgently needed. Materials & methods: We developed radioimmunotherapy of metastatic melanoma using 6D2 monoclonal antibody (mAb) to melanin with encouraging therapeutic results, preclinically and in patients. Results: We observed tumor suppression with the unlabeled 6D2 mAb and investigated its tumoricidal mechanisms. In melanoma tumor-bearing mice, we detected more complement-C3 deposition in the tumors from 188-rhenium-labeled 6D2 mAb-treated mice when compared with untreated controls. 6D2 and isotype-control mAb TEPC caused suppression of tumor growth in A2058 melanoma tumor-bearing mice. Tumors of mice treated with the unlabeled 6D2 mAb were infiltrated with more lymphocytes compared with controls. In vitro antibody-dependent cell-mediated cytotoxicity did not contribute to the tumor-suppressive effect of 6D2 mAb, while 6D2 mAb demonstrated a strong effect on initiating complement-dependent cytotoxicity. Conclusion: We concluded that 6D2 mAb mediated complement-dependent cytotoxicity, resulting in killing of the tumor cells and suppression of tumor growth. These observations will help to improve the treatment protocols of radioimmunotherapy, as well as immunotherapy.

Original languageEnglish (US)
Pages (from-to)357-364
Number of pages8
JournalImmunotherapy
Volume5
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Radioimmunotherapy
Melanins
Melanoma
Monoclonal Antibodies
Antibodies
Neoplasms
Rhenium
Antibody-Dependent Cell Cytotoxicity
Complement C3
Clinical Protocols
Growth
Immunotherapy
Lymphocytes

Keywords

  • ADCC
  • antibody-dependent cell-mediated cytotoxicity
  • CDC
  • complement system
  • complement-dependent cytotoxicity
  • immunotherapy
  • melanoma
  • radioimmunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Jandl, T., Revskaya, E., Jiang, Z., Bryan, R. A., Casadevall, A., & Dadachova, E. (2013). Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma. Immunotherapy, 5(4), 357-364. https://doi.org/10.2217/imt.13.16

Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma. / Jandl, Thomas; Revskaya, Ekaterina; Jiang, Zewei; Bryan, Ruth A.; Casadevall, Arturo; Dadachova, Ekaterina.

In: Immunotherapy, Vol. 5, No. 4, 04.2013, p. 357-364.

Research output: Contribution to journalArticle

Jandl, T, Revskaya, E, Jiang, Z, Bryan, RA, Casadevall, A & Dadachova, E 2013, 'Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma', Immunotherapy, vol. 5, no. 4, pp. 357-364. https://doi.org/10.2217/imt.13.16
Jandl, Thomas ; Revskaya, Ekaterina ; Jiang, Zewei ; Bryan, Ruth A. ; Casadevall, Arturo ; Dadachova, Ekaterina. / Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma. In: Immunotherapy. 2013 ; Vol. 5, No. 4. pp. 357-364.
@article{a1565e7626c041379f0b610784618049,
title = "Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma",
abstract = "Aim: Novel treatments for metastatic melanoma are urgently needed. Materials & methods: We developed radioimmunotherapy of metastatic melanoma using 6D2 monoclonal antibody (mAb) to melanin with encouraging therapeutic results, preclinically and in patients. Results: We observed tumor suppression with the unlabeled 6D2 mAb and investigated its tumoricidal mechanisms. In melanoma tumor-bearing mice, we detected more complement-C3 deposition in the tumors from 188-rhenium-labeled 6D2 mAb-treated mice when compared with untreated controls. 6D2 and isotype-control mAb TEPC caused suppression of tumor growth in A2058 melanoma tumor-bearing mice. Tumors of mice treated with the unlabeled 6D2 mAb were infiltrated with more lymphocytes compared with controls. In vitro antibody-dependent cell-mediated cytotoxicity did not contribute to the tumor-suppressive effect of 6D2 mAb, while 6D2 mAb demonstrated a strong effect on initiating complement-dependent cytotoxicity. Conclusion: We concluded that 6D2 mAb mediated complement-dependent cytotoxicity, resulting in killing of the tumor cells and suppression of tumor growth. These observations will help to improve the treatment protocols of radioimmunotherapy, as well as immunotherapy.",
keywords = "ADCC, antibody-dependent cell-mediated cytotoxicity, CDC, complement system, complement-dependent cytotoxicity, immunotherapy, melanoma, radioimmunotherapy",
author = "Thomas Jandl and Ekaterina Revskaya and Zewei Jiang and Bryan, {Ruth A.} and Arturo Casadevall and Ekaterina Dadachova",
year = "2013",
month = "4",
doi = "10.2217/imt.13.16",
language = "English (US)",
volume = "5",
pages = "357--364",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Complement-dependent cytotoxicity of an antibody to melanin in radioimmunotherapy of metastatic melanoma

AU - Jandl, Thomas

AU - Revskaya, Ekaterina

AU - Jiang, Zewei

AU - Bryan, Ruth A.

AU - Casadevall, Arturo

AU - Dadachova, Ekaterina

PY - 2013/4

Y1 - 2013/4

N2 - Aim: Novel treatments for metastatic melanoma are urgently needed. Materials & methods: We developed radioimmunotherapy of metastatic melanoma using 6D2 monoclonal antibody (mAb) to melanin with encouraging therapeutic results, preclinically and in patients. Results: We observed tumor suppression with the unlabeled 6D2 mAb and investigated its tumoricidal mechanisms. In melanoma tumor-bearing mice, we detected more complement-C3 deposition in the tumors from 188-rhenium-labeled 6D2 mAb-treated mice when compared with untreated controls. 6D2 and isotype-control mAb TEPC caused suppression of tumor growth in A2058 melanoma tumor-bearing mice. Tumors of mice treated with the unlabeled 6D2 mAb were infiltrated with more lymphocytes compared with controls. In vitro antibody-dependent cell-mediated cytotoxicity did not contribute to the tumor-suppressive effect of 6D2 mAb, while 6D2 mAb demonstrated a strong effect on initiating complement-dependent cytotoxicity. Conclusion: We concluded that 6D2 mAb mediated complement-dependent cytotoxicity, resulting in killing of the tumor cells and suppression of tumor growth. These observations will help to improve the treatment protocols of radioimmunotherapy, as well as immunotherapy.

AB - Aim: Novel treatments for metastatic melanoma are urgently needed. Materials & methods: We developed radioimmunotherapy of metastatic melanoma using 6D2 monoclonal antibody (mAb) to melanin with encouraging therapeutic results, preclinically and in patients. Results: We observed tumor suppression with the unlabeled 6D2 mAb and investigated its tumoricidal mechanisms. In melanoma tumor-bearing mice, we detected more complement-C3 deposition in the tumors from 188-rhenium-labeled 6D2 mAb-treated mice when compared with untreated controls. 6D2 and isotype-control mAb TEPC caused suppression of tumor growth in A2058 melanoma tumor-bearing mice. Tumors of mice treated with the unlabeled 6D2 mAb were infiltrated with more lymphocytes compared with controls. In vitro antibody-dependent cell-mediated cytotoxicity did not contribute to the tumor-suppressive effect of 6D2 mAb, while 6D2 mAb demonstrated a strong effect on initiating complement-dependent cytotoxicity. Conclusion: We concluded that 6D2 mAb mediated complement-dependent cytotoxicity, resulting in killing of the tumor cells and suppression of tumor growth. These observations will help to improve the treatment protocols of radioimmunotherapy, as well as immunotherapy.

KW - ADCC

KW - antibody-dependent cell-mediated cytotoxicity

KW - CDC

KW - complement system

KW - complement-dependent cytotoxicity

KW - immunotherapy

KW - melanoma

KW - radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84875931508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875931508&partnerID=8YFLogxK

U2 - 10.2217/imt.13.16

DO - 10.2217/imt.13.16

M3 - Article

VL - 5

SP - 357

EP - 364

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 4

ER -